Do Kim

After strong performance in 2020, biopharma stocks are expected to continue their winning run in the new year. Among the companies in the space, analysts at BMO Capital Markets are particularly bullish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN and Constellation Pharmaceuticals Inc (NASDAQ...

Biotech Replimune Group, Inc. (NASDAQ: REPL), which conducts research and cancer treatment studies using oncolytic viruses, picked up a sell-side bull Tuesday. The Analyst BMO Capital Markets analyst Do Kim initiated coverage of Replimune Group with an Outperform rating and $31 price target. The...

The development-stage biotechnology company Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) uses protein interaction to treat myelofibrosis, in addition to addressing prostate cancer and other tumors. The Analysts Oppenheimer analyst Leah Rush Cann initiated coverage of ...

As Scholar Rock Holding Corp (NASDAQ: SRRK)’s IPO quiet period expired Monday, four analysts came out with bullish recommendations on the stock. Here’s what one of them had to say. The Rating BMO Capital Markets analyst Do Kim initiated coverage with an Outperform rating and $31...

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced Tuesday the approval of its Tavalisse for chronic immune thrombocytopenia — an achievement prompting a 14-percent pop in its stock price. Analysts echoed investor enthusiasm, with H.C. Wainwright increasing its price target from $6.70 to $8...

BioXcel Therapeutics Inc (NASDAQ: BTAI) recently went public, offering 5.45 million shares at $11 each.  The Analyst BMO Capital Markets analyst Do Kim initiated coverage of BioXcel Therapeutics with an Outperform rating and $23 price target, suggesting 125-percent return potential....

VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on the Street predict Buy-worthy data — “free call options.” The Rating BMO...

BMO Capital raised its price target on Ionis Pharmaceuticals Inc (NASDAQ: IONS) shares to $68 from $61 after the brokerage increased its Spinraza estimates to reflect a faster ramp based on the broad approval and a higher price point announced by partner Biogen Inc (NASDAQ: BIIB). Spinraza To...

Shares of Retrophin Inc (NASDAQ: RTRX) climbed more than 4 percent after it gave positive updated DUET data at the ASN meeting. Following this development, BMO analyst Do Kim raised the price target of the Outperform-rated Retrophin shares to $46 from $40. The revised target price implies...

BMO Capital's Do Kim initiated Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) at Outperform with a lofty $4.00 price target. Kim believes upcoming Phase III data in August may drive "significant upside to shares." The analyst was especially hopeful for the near-term data readout for lead drug...

As multiple suitors line up to acquire Medivation Inc (NASDAQ: MDVN), BMO Capital said a winning bid will require an acceptable value for Talazoparib, likely a premium over the $410 million upfront payment to BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). The Talazoparib Issue Last year, Medivation...

Shares of Ionis Pharmaceuticals Inc (NASDAQ: IONS) lost 39.42 percent on Thursday after the company announced that GlaxoSmithKline plc (ADR) (NYSE: GSK), which has the option to license the company’s IONIS-TTRx — currently undergoing a Phase 3 trial, has decided not to initiate a Stage...